Histologically confirmed locally advanced or metastatic urothelial carcinoma (LA/mUC).
Measurable disease per RECIST v1.1 criteria.
ECOG performance status of 0 or 1.
Adequate organ function, including hematologic, hepatic, and renal parameters.
Willingness to comply with study procedures and provide informed consent.
For participants of childbearing potential: agreement to use effective contraception during the study and for a defined period after the last dose.
You may not be if
Participants will be excluded if they meet any of the following:
History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
Known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression
Active autoimmune diseases requiring systemic treatment within the past 2 years
Participation in another investigational study within 30 days or 5 half-lives of the investigational product.
Pregnant or breastfeeding individuals.
Inability or unwillingness to comply with study requirements.
Study staff or their immediate family members directly involved in the conduct of the study.
Clareo Health | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
